2020 Cardiotoxicity Pipeline Insight Report: Present Clinical Development Scenario and Growth Prospects

Dublin, Feb. 18, 2020 (GLOBE NEWSWIRE) -- The "Cardiotoxicity - Pipeline Insight, 2020" report has been added to ResearchAndMarkets.com's offering.

Cardiotoxicity Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Cardiotoxicity market.

A detailed picture of the Cardiotoxicity pipeline landscape is provided, which includes the disease overview and Cardiotoxicity treatment guidelines. The assessment part of the report embraces in-depth Cardiotoxicity commercial assessment and clinical assessment of the Cardiotoxicity pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cardiotoxicity collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

• All of the companies that are developing therapies for the treatment of Cardiotoxicity with aggregate therapies developed by each company for the same.
• Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Cardiotoxicity treatment.
• Cardiotoxicity key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Cardiotoxicity market.

Scope of the Report

• The Cardiotoxicity report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Cardiotoxicity across the complete product development cycle, including all clinical and nonclinical stages.
• It comprises of detailed profiles of Cardiotoxicity therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.
• Detailed Cardiotoxicity research and development progress and trial details, results wherever available, are also included in the pipeline study.
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Cardiotoxicity.
  

Key Topics Covered

1. Report Introduction

2. Cardiotoxicity
2.1. Overview
2.2. History
2.3. Cardiotoxicity Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Cardiotoxicity Diagnosis
2.6.1. Diagnostic Guidelines

3. Cardiotoxicity Current Treatment Patterns
3.1. Cardiotoxicity Treatment Guidelines

4. Cardiotoxicity - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Cardiotoxicity companies collaborations, Licensing, Acquisition - Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Cardiotoxicity Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Cardiotoxicity Acquisition Analysis

5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target

6. Cardiotoxicity Late Stage Products (Phase-III)

7. Cardiotoxicity Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Cardiotoxicity Discontinued Products

13. Cardiotoxicity Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table

14. Cardiotoxicity Key Companies

15. Cardiotoxicity Key Products

16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation

17. Cardiotoxicity Unmet Needs

18. Cardiotoxicity Future Perspectives

19. Cardiotoxicity Analyst Review

For more information about this report visit https://www.researchandmarkets.com/r/8m1o1c

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900